Pediatric Clinical Trials
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project).
It is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and to better define clinical characteristics and outcome of the more uncommon subtypes
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell
lymphoma:
- Peripheral T-cell lymphoma unspecified;
- Peripheral T-cell lymphoma, lymphoepithelioid variant;
- Peripheral T-cell lymphoma, T-zone variant ;
- Peripheral T-cell lymphoma, parafollicular variant ;
- Angioimmunoblastic T-cell lymphoma;
- Nasal NK/T-cell lymphoma;
- NK/T-cell lymphoma, nasal time;
- Anaplastic large-cell lymphoma, T/null cell, ALK+, primary systemic type
- Anaplastic large-cell lymphoma, T/null cell, ALK-, primary systemic type
- Anaplastic large cell lymphoma, small cell variant, ALK+
- Anaplastic large cell lymphoma, lymphohistiocytic variant, ALK+
- Enteropathy- type T-cell lymphoma;
- Hepatosplenic T-cell lymphoma;
- Peripheral gamma-delta T-cell lymphoma;
- Subcutaneous panniculitis-like T-cell lymphoma;
- Unclassifiable peripheral T-cell Lymphoma
- Unclassifiable NK-cell lymphoma
2. Age over 18
3. Tissue biopsies adequate for diagnosis and classification and available for
centralized review
4. Clinical data including baseline information on disease localization and laboratory
parameters at staging, features of treatment adopted and assurance of follow-up
updating for at least 5 years are requested
5. Written informed consent
Exclusion Criteria:
1. Age < 18
2. Diagnosis of T-cell or NK-cell leukemia or proliferation and other than mature types
including:
- Adult T-cell leukemia/lymphoma;
- Blastic NK-cell leukemia/lymphoma;
- Aggressive NK-cell leukemia
- T-cell large granular lymphocytic leukemia
- T-cell large granular lymphocytic proliferation
- NK-cell large granular lymphocytic proliferation
- T-cell prolymphocytic leukemia
- Precursor T-cell lymphoblastic leukemia/lymphoma
- Mycosis fungoides;
- Sézary syndrome;
- Primary cutaneous ALCL
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting